Six startups tracing their foundation to University of California, Irvine innovation have been selected to give presentations at the 19th Annual SoCalBio Conference, organized by the Southern California Biomedical Council, on September 29 at the Long Beach Hilton. Numerous company screenings took place across the region in program meetings organized by SoCalBio, including a meeting that was held on August 21 at the Cove, home to UCI Applied Innovation, located in the University Research Park. Out of all companies that were screened, only forty were selected to participate in the conference. The UCI-based startups included in the final forty companies were identified as some of the most qualified candidates looking for funding and new alliances.
“A primary focus of UCI Applied Innovation is supporting the partnering and fundraising efforts of our startups by actively securing opportunities for them to present their stories at relevant venues like the SoCalBio Conference,” said Michael Artinger, managing director of the Research Translation Group at Applied Innovation. “I think the inclusion of all six candidate companies speaks highly of the quality of young companies coming out of UCI.”
A premiere event for Southern California bioscience innovation, the SoCalBio conference is attended by industry leaders in pharmaceuticals, biotechnology, medical device, diagnostics, and informatics. Additionally, angel investors, venture capitalists, investment bankers, life-science educators and researchers, service providers, policy makers, economic development professionals and media representatives will also be in attendance.
Participating UCI-based startups include:
• Anvyl, LLC (Therapies for treating cognitive-deficit disorders)
• Aspire BioScience (Endocannabinoid-based therapeutics for treatment of opioid addiction and non-addictive pain management)
• GlyTR Therapeutics (Immunotherapy technology for treating different types of cancer)
• PhageTech, Inc. (Electrochemical biosensor platform for low-cost diagnostic testing)
• Syntr Health Technologies (Stem cells for the prevention and treatment of diabetic foot ulcers)
• Velox Biosystems (Instrument for the rapid diagnosis of sepsis and antibiotic resistance)
According to Ahmed Zobi, CEO of Syntr Health Technologies, “By participating in the SoCalBio conference, we hope to make connections with potential partners in the industry and begin the first steps in preparing for any future investments into our company. Through the pitch screening event, we had a great amount of positive feedback on the way we presented. At the same time, we were given tips on what to include on September 29th.”
“We are pleased to have so many promising UCI spinouts presenting at the 19th Annual SoCalBio Conference,” said SoCalBio President and CEO Ahmed Enany. “They’re part of a presenting company lineup that exhibits the strength and future of Southern California’s bioscience industry.”
Caption for image above: Attendees listening to UCI startups present their companies at the SoCalBio Catalyst Program Meeting held last month in conjunction with Applied Innovation at the Cove.